182 related articles for article (PubMed ID: 15253689)
21. Long-term efficacy of biologics in the treatment of psoriasis: what do we really know?
Alwawi EA; Krulig E; Gordon KB
Dermatol Ther; 2009; 22(5):431-40. PubMed ID: 19845720
[TBL] [Abstract][Full Text] [Related]
22. Combining systemic retinoids with biologic agents for moderate to severe psoriasis.
Smith EC; Riddle C; Menter MA; Lebwohl M
Int J Dermatol; 2008 May; 47(5):514-8. PubMed ID: 18412874
[TBL] [Abstract][Full Text] [Related]
23. Outcomes associated with the use of biologic agents in moderate to severe psoriasis.
Price J; Bhosle M; Feldman SR; Balkrishnan R
J Drugs Dermatol; 2007 Mar; 6(3):259-67. PubMed ID: 17373187
[TBL] [Abstract][Full Text] [Related]
24. Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis.
de Miguel R; el-Azhary R
Int J Dermatol; 2009 Jun; 48(6):653-8. PubMed ID: 19538381
[No Abstract] [Full Text] [Related]
25. Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine.
Opmeer BC; Heydendael VM; De Borgie CA; Spuls PI; Bossuyt PM; Bos JD; De Rie MA
Arch Dermatol; 2004 Jun; 140(6):685-90. PubMed ID: 15210458
[TBL] [Abstract][Full Text] [Related]
26. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
Langley RG
J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
[TBL] [Abstract][Full Text] [Related]
27. Disease and treatment burden of psoriasis: examining the impact of biologics.
Raval K; Lofland JH; Waters H; Piech CT
J Drugs Dermatol; 2011 Feb; 10(2):189-96. PubMed ID: 21283925
[TBL] [Abstract][Full Text] [Related]
28. Managed care aspects of psoriasis and psoriatic arthritis.
Evans C
Am J Manag Care; 2016 Jun; 22(8 Suppl):s238-43. PubMed ID: 27356195
[TBL] [Abstract][Full Text] [Related]
29. Economic considerations in psoriasis management.
Radtke MA; Augustin M
Clin Dermatol; 2008; 26(5):424-31. PubMed ID: 18755360
[TBL] [Abstract][Full Text] [Related]
30. Management and costs of severe psoriasis: the role of new biologics.
Feldman SR; Pearce DJ
Expert Rev Pharmacoecon Outcomes Res; 2004 Oct; 4(5):573-9. PubMed ID: 19807550
[TBL] [Abstract][Full Text] [Related]
31. [Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis].
Ara M; Pérez A; Ferrando J
Actas Dermosifiliogr; 2011 Nov; 102(9):706-16. PubMed ID: 21600532
[TBL] [Abstract][Full Text] [Related]
32. Use of biologic agents in pediatric psoriasis.
Marji JS; Marcus R; Moennich J; Mackay-Wiggan J
J Drugs Dermatol; 2010 Aug; 9(8):975-86. PubMed ID: 20684148
[TBL] [Abstract][Full Text] [Related]
33. Alefacept for the treatment of psoriasis and other dermatologic diseases.
Strober BE; Menon K
Dermatol Ther; 2007; 20(4):270-6. PubMed ID: 17970892
[TBL] [Abstract][Full Text] [Related]
34. [Analysis of the cost effectiveness of home-based phototherapy with narrow-band UV-B radiation compared with biological drugs for the treatment of moderate to severe psoriasis].
Vañó-Galván S; Gárate MT; Fleta-Asín B; Hidalgo A; Fernández-Guarino M; Bermejo T; Jaén P
Actas Dermosifiliogr; 2012 Mar; 103(2):127-37. PubMed ID: 22036021
[TBL] [Abstract][Full Text] [Related]
35. Treatment of moderate to severe plaque psoriasis with biologics: analysis of the additional cost of temporary dose escalation vs switch to another biologic after failure of maintenance therapy.
Puig L
Actas Dermosifiliogr; 2014 May; 105(4):401-12. PubMed ID: 24444743
[TBL] [Abstract][Full Text] [Related]
36. Treatment of moderate-to-severe plaque psoriasis.
Salgo R; Thaçi D
G Ital Dermatol Venereol; 2009 Dec; 144(6):701-11. PubMed ID: 19907408
[TBL] [Abstract][Full Text] [Related]
37. Could anti IL12/23 therapy replace anti-TNF biologics?
Ionescu MA; Lipozencić J
Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
[TBL] [Abstract][Full Text] [Related]
38. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies.
Pearce DJ; Nelson AA; Fleischer AB; Balkrishnan R; Feldman SR
J Dermatolog Treat; 2006; 17(1):29-37. PubMed ID: 16467021
[TBL] [Abstract][Full Text] [Related]
39. Is 'class effect' relevant when assessing the benefit/risk profile of a biologic agent?
Sterry W; van de Kerkhof P
J Eur Acad Dermatol Venereol; 2012 Aug; 26 Suppl 5():9-16. PubMed ID: 22758912
[TBL] [Abstract][Full Text] [Related]
40. Treatment and management of psoriasis with nail involvement: a focus on biologic therapy.
Langley RG; Daudén E
Dermatology; 2010; 221 Suppl 1():29-42. PubMed ID: 20733313
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
